Assets Held for Sale	6 Months Ended
Jun. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
Assets Held for Sale	Assets Held for Sale In March 2025, the Company’s board of directors (the “Board of Directors”) approved a plan to sell the Tarzana facility. The Company engaged a broker to facilitate a potential sale of the Tarzana facility and reclassified the Tarzana facility as held for sale in the consolidated balance sheet during the year ended December 31, 2025. The Tarzana facility is currently leased to AstraZeneca Pharmaceuticals LP (“Tenant”) and Tenant has a right of first offer to purchase it. Refer to Note 9. In May 2026, the Company determined that there had been a change to its plan with respect to the Tarzana facility. As a result, management concluded that the facility no longer met the criteria for classification as held for sale under ASC 360. Consequently, in May 2026, the Tarzana facility was reclassified as held and used and resumed depreciating the asset subject to depreciation prospectively over its remaining estimated useful life. In accordance with ASC 360, a long lived asset that ceases to be classified as held for sale is measured at the lower of (a) its carrying amount before the asset was classified as held for sale, adjusted for depreciation expenses that would have been recognized had the asset been continuously classified as held and used, and (b) its fair value. The Company determined the adjusted carrying amount of the Tarzana facility to be $111.9 million, which includes $3.6 million of depreciation expense, recorded within “restructuring and impairment charges, net”, that would have been recognized had the asset been continuously classified as held and used. In accordance with ASC 360, the building and land of the Tarzana facility were measured individually when the assets were placed back into use. The Company estimated the fair value of the Tarzana facility, including separate estimates of the fair value of the land and building, using a combination of the income capitalization approach and the sales comparison approach. These valuations represent Level 3 fair value measurements within the fair value hierarchy established by ASC 820, as each relied on significant unobservable inputs. The estimated fair value of the building exceeded its adjusted carrying amount; therefore, the building was recorded at its adjusted carrying amount in accordance with ASC 360. The estimated fair value of the land was below its adjusted carrying amount and was therefore recorded at fair value. These fair value measurements are nonrecurring and were performed solely in connection with the reclassification described above. The Company recognized a net remeasurement loss of $0.2 million related to the reclassification of the Tarzana facility from held for sale to held and used. The land was recorded at its estimated fair value of $20.4 million at the date of reclassification, while the building was recorded at its adjusted carrying amount of $91.5 million, representing its carrying value prior to classification as held for sale adjusted for depreciation that would have been recognized had the asset remained classified as held and used. The net remeasurement loss consisted of an $8.1 million impairment loss on the Tarzana facility, comprised of a $4.5 million reduction in the carrying value of the land to fair value and a $3.6 million depreciation charge that would have been recognized had the building remained classified as held and used, partially offset by a $7.9 million remeasurement benefit resulting from the reversal of previously recognized estimated cost to sell. The net remeasurement loss was recorded in the condensed consolidated statements of operations and comprehensive loss in the line item “restructuring and impairment charges, net” for the three and six months ended June 30, 2026, under the same line in which the original impairment and estimated cost to sell charges had been recorded. For the six months ended June 30, 2025, the Company recorded charges related to the Tarzana facility of approximately $16.6 million, consisting of $8.7 million related to impairment and $7.9 million related to the estimated cost to sell. The Company did not record any charges related to the Tarzana facility for the three months ended June 30, 2025. Refer to Note 14. Following the reclassification, the Company recorded the Tarzana facility under “Property, plant and equipment, net” on the Company’s condensed consolidated balance sheet as of June 30, 2026. In addition, one month of depreciation of $0.2 million on the Tarzana facility was recorded in accumulated depreciation, resulting in a carrying value of $111.7 million on the Company’s condensed consolidated balance sheet as of June 30, 2026. The carrying value of the held for sale Tarzana facility was $112.1 million as of December 31, 2025.

In March 2025, the Company’s board of directors (the “Board of Directors”) approved a plan to sell the Tarzana facility. The Company engaged a broker to facilitate a potential sale of the Tarzana facility and reclassified the Tarzana facility as held for sale in the consolidated balance sheet during the year ended December 31, 2025. The Tarzana facility is currently leased to AstraZeneca Pharmaceuticals LP (“Tenant”) and Tenant has a right of first offer to purchase it. Refer to Note 9.

In May 2026, the Company determined that there had been a change to its plan with respect to the Tarzana facility. As a result, management concluded that the facility no longer met the criteria for classification as held for sale under ASC 360. Consequently, in May 2026, the Tarzana facility was reclassified as held and used and resumed depreciating the asset subject to depreciation prospectively over its remaining estimated useful life. In accordance with ASC 360, a long lived asset that ceases to be classified as held for sale is measured at the lower of (a) its carrying amount before the asset was classified as held for sale, adjusted for depreciation expenses that would have been recognized had the asset been continuously classified as held and used, and (b) its fair value. The Company determined the adjusted carrying amount of the Tarzana facility to be $111.9 million, which includes $3.6 million of depreciation expense, recorded within “restructuring and impairment charges, net”, that would have been recognized had the asset been continuously classified as held and used.

In accordance with ASC 360, the building and land of the Tarzana facility were measured individually when the assets were placed back into use. The Company estimated the fair value of the Tarzana facility, including separate estimates of the fair value of the land and building, using a combination of the income capitalization approach and the sales comparison approach. These valuations represent Level 3 fair value measurements within the fair value hierarchy established by ASC 820, as each relied on significant unobservable inputs. The estimated fair value of the building exceeded its adjusted carrying amount; therefore, the building was recorded at its adjusted carrying amount in accordance with ASC 360. The estimated fair value of the land was below its adjusted carrying amount and was therefore recorded at fair value. These fair value measurements are nonrecurring and were performed solely in connection with the reclassification described above.

The Company recognized a net remeasurement loss of $0.2 million related to the reclassification of the Tarzana facility from held for sale to held and used. The land was recorded at its estimated fair value of $20.4 million at the date of reclassification, while the building was recorded at its adjusted carrying amount of $91.5 million, representing its carrying value prior to classification as held for sale adjusted for depreciation that would have been recognized had the asset remained classified as held and used. The net remeasurement loss consisted of an $8.1 million impairment loss on the Tarzana facility, comprised of a $4.5 million reduction in the carrying value of the land to fair value and a $3.6 million depreciation charge that would have been recognized had the building remained classified as held and used, partially offset by a $7.9 million remeasurement benefit resulting from the reversal of previously recognized estimated cost to sell. The net remeasurement loss was recorded in the condensed consolidated statements of operations and comprehensive loss in the line item “restructuring and impairment charges, net” for the three and six months ended June 30, 2026, under the same line in which the original impairment and estimated cost to sell charges had been recorded.

For the six months ended June 30, 2025, the Company recorded charges related to the Tarzana facility of approximately $16.6 million, consisting of $8.7 million related to impairment and $7.9 million related to the estimated cost to sell. The Company did not record any charges related to the Tarzana facility for the three months ended June 30, 2025. Refer to Note 14.

Following the reclassification, the Company recorded the Tarzana facility under “Property, plant and equipment, net” on the Company’s condensed consolidated balance sheet as of June 30, 2026. In addition, one month of depreciation of $0.2 million on the Tarzana facility was recorded in accumulated depreciation, resulting in a carrying value of $111.7 million on the Company’s condensed consolidated balance sheet as of June 30, 2026. The carrying value of the held for sale Tarzana facility was $112.1 million as of December 31, 2025.